Replies to post #236692 on Biotech Values

[dewophile]

I bet if ENTA wanted to they could find a partner for HBV (and probably RSV) which would then validate the program(s) in the eyes of the market. The fact they don't need the cash in the early going, which is a good thing, is ironically hurting the valuation of these assets
JMO